The Use of Anthracyclines for Therapy of CNS Tumors

Author(s): Martina da Ros, Anna Lisa Iorio, Maurizio Lucchesi, Alessia Stival, Maurizio de Martino, Iacopo Sardi

Journal Name: Anti-Cancer Agents in Medicinal Chemistry
(Formerly Current Medicinal Chemistry - Anti-Cancer Agents)

Volume 15 , Issue 6 , 2015

Become EABM
Become Reviewer

Graphical Abstract:


Despite being long lived, anthracyclines remain the “evergreen” drugs in clinical practice of oncology, showing a potent effect in inhibiting cell growth in many types of tumors, including brain neoplasms. Unfortunately, they suffer from a poor penetration into the brain when intravenously administered due to multidrug resistance mechanism, which hampers their delivery across the blood brain barrier.

In this paper, we summarize the current literature on the role of anthracyclines in cancer therapy and highlight recent efforts on 1) development of tumor cell resistance to anthracyclines and 2) the new approaches to brain drug delivery across the blood brain barrier.

Keywords: Anthracyclines, blood brain barrier, brain diseases, drug delivery systems, drug efflux proteins, multidrug resistance.

open access plus

Rights & PermissionsPrintExport Cite as

Article Details

Year: 2015
Published on: 10 June, 2015
Page: [721 - 727]
Pages: 7
DOI: 10.2174/1871520615666150407155319

Article Metrics

PDF: 58